Melanosis after prolonged chlorpromazine therapy.

Area of Science:

• Pharmacology
• Dermatology
• Psychiatry

Background:

• Chlorpromazine is a typical antipsychotic used for chronic psychiatric conditions.
• Skin pigmentation changes can be a side effect of certain medications.
• Melanin concentration is a key factor in skin color and UV protection.

Purpose of the Study:

• To investigate the effect of prolonged high-dose chlorpromazine treatment on skin melanin concentration.
• To compare melanin levels between treated psychiatric patients and controls.
• To identify demographic or site-specific differences in chlorpromazine-induced melanosis.

Main Methods:

• Quantitative measurement of skin melanin using reflectance spectrophotometry.
• Comparison of 201 chronic psychiatric patients (predominantly schizophrenics) receiving chlorpromazine with 161 controls.
• Inclusion of both White and Black participants of both sexes.

Main Results:

• Significantly higher skin melanin concentrations were observed in chlorpromazine-treated patients compared to controls.
• Melanin level increases were more pronounced in female patients.
• Differences were particularly marked in exposed skin areas of White participants.

Conclusions:

• Prolonged high-dose chlorpromazine treatment can lead to increased skin melanin (melanosis).
• The observed melanosis may be influenced by sex and skin exposure.
• Further research into the etiology of chlorpromazine-induced melanosis is warranted.